List of Excipients in Branded Drug FLUVASTATIN SODIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	FLUVASTATIN SODIUM	fluvastatin sodium	0781-5370	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	FLUVASTATIN SODIUM	fluvastatin sodium	0781-5370	FERRIC OXIDE YELLOW
Sandoz Inc	FLUVASTATIN SODIUM	fluvastatin sodium	0781-5370	HYDROXYPROPYL CELLULOSE

Generic Drugs Containing FLUVASTATIN SODIUM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	fluvastatin sodium	0093-7446	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	fluvastatin sodium	0093-7446	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	fluvastatin sodium	0093-7446	HYDROXYETHYL CELLULOSE

What are the Most Frequently-Used Excipients in FLUVASTATIN SODIUM?

# Of NDCs	Excipient
3	AMMONIA
1	CELLULOSE, MICROCRYSTALLINE
4	CROSPOVIDONE

Fluvastatin Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

Fluvastatin sodium is a mature, off-patent statin with established immediate-release capsule and extended-release tablet platforms. The strongest excipient opportunities are not in basic generic substitution, where price competition is intense, but in differentiated oral delivery: controlled release, improved tablet robustness, swallowability, low-dose flexibility, and formulation platforms that reduce food-effect or gastrointestinal variability. The active ingredient has no biosimilar pathway, and core composition-of-matter exclusivity has expired.

What is the commercial status of fluvastatin sodium?

Fluvastatin sodium is the sodium salt of fluvastatin, an HMG-CoA reductase inhibitor marketed originally as Lescol and Lescol XL by Novartis. The product was approved in the United States in 1993, with the extended-release 80 mg tablet approved later.[1]

Attribute	Fluvastatin sodium
Therapeutic class	HMG-CoA reductase inhibitor
Main indications	Hypercholesterolemia and mixed dyslipidemia
Original brand	Lescol
Extended-release brand	Lescol XL
Immediate-release strengths	20 mg and 40 mg capsules
Extended-release strength	80 mg tablet
Administration	Oral
Primary metabolism	CYP2C9
Regulatory pathway for generics	ANDA
Biosimilar pathway	Not applicable
Core patent position	Expired
Current market structure	Generic, price-sensitive, low-growth

Fluvastatin has a smaller commercial market than atorvastatin, rosuvastatin, or simvastatin. Its commercial value is concentrated in generic supply, contract manufacturing, hospital and institutional tenders, and niche reformulations rather than branded primary-care expansion.

What patents protect fluvastatin sodium?

The fundamental fluvastatin patent estate is expired. The original fluvastatin patent family included U.S. Patent No. 4,739,073, assigned to Sandoz, the predecessor of Novartis. The patent was filed in the mid-1980s and had an original term that placed expiration in the mid-2000s, subject to applicable term adjustments and extensions.[2]

Key patent conclusions are:

Patent category	Commercial status
Fluvastatin active ingredient	Expired
Fluvastatin sodium composition	Expired
Original Lescol formulation patents	Expired
Lescol XL extended-release platform patents	Expired or commercially ineffective
Current generic entry barrier	Primarily manufacturing, regulatory, and commercial
New excipient patent opportunity	Possible only through a genuinely differentiated formulation

A new excipient combination cannot restore exclusivity to the active ingredient. Patent protection would need to cover a novel formulation, release mechanism, manufacturing process, stability profile, or clinically meaningful performance characteristic.

When does fluvastatin sodium lose exclusivity?

Fluvastatin sodium lost meaningful market exclusivity years ago. U.S. generic versions entered through the ANDA pathway, and the product is no longer dependent on an active small-molecule exclusivity period.

The practical exclusivity timeline is:

Milestone	Approximate timing
Original U.S. approval of Lescol	1993
Extended-release Lescol XL approval	2000
Core patent expiry	Mid-2000s
Generic availability	Early 2000s onward
Current exclusivity	None of material commercial significance

The relevant commercial question is no longer when generic entry can occur. It is whether a supplier can achieve competitive cost, reliable quality, and differentiated dosage-form performance.

What is the FDA regulatory and Orange Book status of fluvastatin sodium?

Fluvastatin sodium is regulated as a small-molecule drug. Generic products generally use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product.

The FDA Orange Book has historically listed Lescol and Lescol XL reference products and their associated patents. Because the listed patent terms have expired, Orange Book patents do not create a current barrier comparable to an active protected brand product.[3]

The regulatory priorities for an excipient-based fluvastatin product are:

1. Demonstrating sameness or bioequivalence for an ANDA product.
2. Controlling dissolution across the full release profile.
3. Showing acceptable stability of the sodium salt.
4. Managing nitrosamine, elemental impurity, microbial, and residual-solvent risk where relevant.
5. Establishing impurity controls for degradation products.
6. Supporting excipient functionality and supplier qualification.

A formulation that materially changes release behavior, dosing frequency, indication, or clinical performance may fall outside a conventional ANDA strategy and require a 505(b)(2) application.

What excipients are used in fluvastatin sodium formulations?

Commercial formulations use conventional oral excipients. Exact compositions vary by manufacturer, strength, dosage form, and manufacturing site.

Immediate-release capsules

Typical functional excipient categories include:

Excipient category	Formulation purpose
Microcrystalline cellulose	Diluent and compactability
Pregelatinized starch or starch	Filler, binder, and disintegration support
Povidone or related binder	Granulation and mechanical strength
Magnesium stearate	Lubrication
Colloidal silicon dioxide	Flow improvement
Sodium bicarbonate or alkaline modifier	Microenvironmental pH control
Talc	Processing and anti-adherence
Gelatin	Capsule shell
Titanium dioxide and iron oxides	Capsule color and identification

The FDA label for Lescol identifies conventional capsule excipients, including gelatin, microcrystalline cellulose, magnesium stearate, pregelatinized starch, talc, titanium dioxide, and colorants.[1] DailyMed product records should be used for manufacturer-specific inactive-ingredient verification because generic formulations are not required to use the same excipient system as the reference product.[4]

Extended-release tablets

The Lescol XL platform uses a hydrophilic matrix approach. Common functional categories include:

Excipient category	Formulation purpose
Hypromellose	Matrix former controlling hydration and diffusion
Microcrystalline cellulose	Diluent and tablet structure
Hydroxypropyl cellulose	Binder or matrix-support polymer
Povidone	Binding and granulation
Magnesium stearate	Lubrication
Talc	Processing aid
Titanium dioxide and iron oxides	Film-coating color
Sodium bicarbonate or alkaline excipient	Microenvironmental pH control

The extended-release product is the more valuable formulation reference because it demonstrates that fluvastatin sodium can support a once-daily modified-release product despite the availability of immediate-release capsules.[1]

What formulation challenges affect fluvastatin sodium?

Fluvastatin sodium formulation is governed by dose, solubility, permeability, chemical stability, and release control.

Solubility and pH management

Fluvastatin is a weak acid delivered as a sodium salt. The salt form can improve aqueous handling, but formulation performance remains sensitive to pH and microenvironmental conditions. Alkaline excipients such as sodium bicarbonate may support dissolution or stabilize the local formulation environment.

A practical development program should test:

• Dissolution in multiple pH media.
• Salt-to-free-acid conversion during storage.
• Moisture uptake.
• Interaction with alkaline and hygroscopic excipients.
• Degradation under heat, light, and humidity.
• Drug distribution in direct-compression and granulation processes.

Extended-release control

For an extended-release tablet, the main technical risk is dose dumping or excessive sensitivity to food and agitation. Polymer concentration, viscosity grade, tablet porosity, compression force, and coating permeability all affect release.

Hydrophilic matrix systems offer low-cost manufacturing but may have narrower release-control tolerances than multiparticulate or osmotic platforms. A differentiated product could use:

• High-viscosity hypromellose.
• Polyethylene oxide matrices.
• pH-independent polymer combinations.
• Multiparticulate pellets in capsules.
• Coated minitablets.
• Osmotic delivery systems.
• Lipid-polymer matrices.

Each platform increases development and manufacturing complexity. The commercial return must justify that complexity in a low-priced generic market.

What excipient strategy is most attractive?

The most defensible strategy is a tiered portfolio rather than a single formulation.

Strategy	Technical value	Commercial potential	Regulatory burden
Low-cost immediate-release capsule	Low	Low to moderate	Low
Direct-compression tablet	Moderate	Moderate	Low to moderate
Taste-masked or easy-swallow tablet	Moderate	Moderate	Moderate
Once-daily matrix tablet	High	Moderate	Moderate to high
Multiparticulate modified-release capsule	High	Niche to moderate	High
Pediatric liquid or sprinkle formulation	High	Niche	Moderate to high
Abuse-deterrent or specialty platform	Low	Low	High

Low-cost generic strategy

A standard immediate-release capsule should emphasize:

• Robust powder flow.
• Low lubricant sensitivity.
• High-speed encapsulation.
• Low moisture exposure.
• Broad supplier availability.
• Minimal use of expensive proprietary excipients.

The best opportunity is usually manufacturing efficiency rather than patent differentiation.

Extended-release strategy

An improved once-daily tablet could target:

• Narrower interpatient release variability.
• Lower food effect.
• Reduced tablet size.
• Improved mechanical strength.
• Lower friability.
• More consistent dissolution after long-term storage.

A new matrix system may support composition or process patents if it produces a measurable and reproducible technical effect. Patent claims should focus on polymer ratios, release profiles, manufacturing parameters, or stability results rather than generic use of hypromellose.

Pediatric and dysphagia strategy

Fluvastatin has a potential formulation niche in patients who cannot swallow conventional capsules or tablets. Candidate products include:

• Sprinkle capsules.
• Mini-tablets.
• Orally disintegrating tablets.
• Taste-masked granules.
• Low-volume oral suspensions.

The commercial opportunity is limited by the size of the patient population and competition from better-known statins. A pediatric or dysphagia product would need a clear dosing, adherence, or administration advantage.

What formulation patents could protect a new fluvastatin product?

A viable formulation patent would need a technical distinction from expired Lescol and Lescol XL disclosures.

Potential claim themes include:

1. A defined polymer matrix with a specified dissolution profile.
2. A multiparticulate system with controlled coating thickness.
3. A low-moisture formulation that improves chemical stability.
4. A tablet with reduced food-effect variability.
5. A pediatric dosage form with taste masking and dose uniformity.
6. A process that improves content uniformity at low dose.
7. A formulation that reduces degradation impurities during accelerated storage.
8. A combination of excipients that enables direct compression at commercial scale.

Weak claim themes include simply substituting one conventional filler for another, using a standard capsule shell, or selecting an ordinary lubricant without demonstrated performance improvement.

Are there Paragraph IV challenges for fluvastatin sodium?

Paragraph IV litigation is not a current strategic feature of the fluvastatin market. The principal patents associated with the original product have expired, and generic products have been commercially available for many years.

For a new formulation, Paragraph IV risk depends on whether the product relies on an active Orange Book-listed patent associated with the reference product. A developer pursuing a 505(b)(2) product could face patent certification issues if it references a listed drug and seeks approval for a formulation or method covered by surviving patents. The risk is substantially lower for a conventional immediate-release generic.

What patent litigation and settlement agreements affect fluvastatin?

The commercially relevant patent disputes were associated with the original branded product and early generic-entry period. Those disputes no longer create a meaningful barrier to ordinary fluvastatin sodium entry.

There is no active biosimilar settlement dynamic because fluvastatin is a synthetic small molecule. Any future dispute would more likely concern:

• A newly patented extended-release formulation.
• A manufacturing process.
• A 505(b)(2) delivery system.
• A method-of-use claim.
• Trade secrets involving scale-up or impurity control.

Which companies are competing in fluvastatin sodium?

The competitive field consists primarily of generic manufacturers, contract manufacturers, distributors, and suppliers of active pharmaceutical ingredient and excipients. Novartis remains historically associated with the reference product, while generic supply has been available from multiple manufacturers.

Competitive differentiation is based on:

• API cost and quality.
• Batch release reliability.
• Dissolution consistency.
• Ability to supply 20 mg, 40 mg, and 80 mg products.
• Packaging and stability performance.
• Institutional tender pricing.
• Regulatory track record.
• Geographic manufacturing footprint.

The principal therapeutic competitors are atorvastatin, simvastatin, pravastatin, rosuvastatin, and pitavastatin. Fluvastatin generally lacks the scale and prescribing momentum of atorvastatin and rosuvastatin, which limits premium pricing for a new excipient system.

What generic entry risks exist for fluvastatin sodium?

The main risks are commercial rather than patent-based.

Price erosion

Generic statins are heavily commoditized. A new formulation may not recover development costs unless it obtains:

• A differentiated dosage form.
• A controlled-release advantage.
• Institutional formulary access.
• A licensing partner with an established generic platform.
• Geographic exclusivity outside the United States.

Bioequivalence failure

Modified-release products face greater risk than immediate-release capsules. Failure modes include:

• Early release during the first hours.
• Inadequate late-stage release.
• Food-dependent dissolution.
• Intersubject pharmacokinetic variability.
• Batch-to-batch changes after scale-up.

Manufacturing barriers

The most material manufacturing barriers are:

• Uniform distribution of low-dose API.
• Consistent polymer hydration.
• Tablet hardness and friability control.
• Compression variability.
• Coating uniformity.
• Moisture protection.
• Control of degradation impurities.

Geographic coverage

The U.S. market is mature. More attractive opportunities may exist in markets where:

• Statin treatment rates are increasing.
• Generic substitution is established.
• Extended-release products have limited competition.
• Local manufacturing is favored.
• Regulatory approval can leverage existing data.

Each jurisdiction has separate requirements for excipient acceptability, bioequivalence, stability, and patent status. A global strategy should not assume that U.S. Orange Book conclusions determine freedom to operate elsewhere.

How strong is the fluvastatin sodium patent estate?

The legacy estate is weak for blocking purposes because the core patents have expired. A new estate could be moderate in strength only if it combines:

• A non-obvious excipient architecture.
• A reproducible release or stability benefit.
• Commercially relevant product claims.
• Process claims that are difficult to design around.
• Data supporting unexpected performance.

Method-of-use patents are less attractive because the major lipid-lowering use is established and heavily served by competing statins. Formulation and manufacturing patents offer better strategic value than broad therapeutic-use claims.

What licensing opportunities exist?

Licensing opportunities are more likely to involve technology than fluvastatin rights. Potential targets include:

• Controlled-release polymer platforms.
• Taste-masking systems.
• Multiparticulate coating technology.
• Continuous manufacturing systems.
• Low-dose content-uniformity processes.
• Stability-enhancing excipient combinations.
• Generic development and commercialization rights in emerging markets.

A license should be evaluated against the low revenue ceiling of fluvastatin. Royalty-bearing technology is difficult to justify for a conventional capsule unless it also applies to a broader portfolio of statins or oral small molecules.

What is the revenue exposure for a new fluvastatin formulation?

Revenue exposure is likely modest for a standard generic and uncertain for a differentiated product.

Product concept	Revenue profile
Conventional 20 mg/40 mg capsule	Volume-driven, low margin
80 mg extended-release tablet	Moderate niche opportunity
Pediatric or dysphagia product	Small population, possible premium
Global low-cost supply	Moderate volume, thin margins
Novel controlled-release platform	Higher price potential, high development risk

The strongest business case is a platform product that uses fluvastatin as an initial application but can be extended to other poorly differentiated oral drugs. A fluvastatin-only excipient investment has limited upside unless development and manufacturing costs are unusually low.

Key Takeaways

• Fluvastatin sodium is a mature, genericized statin with expired core patent protection.
• Immediate-release capsules offer limited formulation differentiation and intense price competition.
• The most credible excipient opportunities involve extended release, low-moisture stability, pediatric administration, and swallowability.
• Hypromellose-based matrix systems are commercially practical but must show measurable performance advantages.
• A new product is more likely to require a conventional ANDA if it remains pharmaceutically equivalent; major formulation changes may require a 505(b)(2) pathway.
• Biosimilar risk is not relevant because fluvastatin is a synthetic small molecule.
• Patent value will depend on formulation architecture, manufacturing process, release profile, and stability data.
• Licensing is more attractive for reusable delivery technology than for fluvastatin-specific rights.
• The commercial ceiling is constrained by competition from atorvastatin, rosuvastatin, simvastatin, pravastatin, and pitavastatin.

FAQs

Can fluvastatin sodium be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could target patients with dysphagia, but taste masking, dose uniformity, mechanical strength, and moisture protection would require dedicated development work.

Is fluvastatin sodium suitable for a pediatric liquid formulation?

It may be suitable, but the formulation would need adequate chemical stability, palatability, dose uniformity, and a regulatory basis for pediatric use. A liquid product could support a niche opportunity rather than a mass-market product.

Which excipient best controls fluvastatin sodium release?

High-viscosity hypromellose is a practical starting point for a hydrophilic matrix tablet. Polyethylene oxide, ethylcellulose coatings, and multiparticulate systems can provide alternative release mechanisms.

Can an excipient supplier patent a fluvastatin sodium formulation?

Yes, if the formulation has novel and non-obvious composition, process, release, stability, or administration claims. Conventional excipient substitution without unexpected performance is unlikely to provide strong protection.

Is fluvastatin sodium a good candidate for a 505(b)(2) product?

It can be, particularly for a differentiated extended-release, pediatric, sprinkle, or dysphagia product. The commercial case depends on whether the new dosage form creates enough clinical or adherence value to offset development and market-access costs.

References

1. U.S. Food and Drug Administration. (2008). Lescol and Lescol XL prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Patent No. 4,739,073. (1988). Trans-6-[2-(3-substituted-1-hydroxypropyl)-5-(substituted phenyl)-3-pyridyl]-2,2-dimethyl-1,3-dioxane-4-carboxylic acids. U.S. Patent and Trademark Office.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. National Library of Medicine. (2024). DailyMed: Fluvastatin sodium drug labels. https://dailymed.nlm.nih.gov/dailymed/